钠-葡萄糖协同转运蛋白2抑制剂在抗衰老机制中的研究进展  

Research progress of sodium-glucose cotransporter 2 inhibitor in anti-aging mechanism

作　　者：韩凤霞 王浩 宁晓暄 Han Fengxia;Wang Hao;Ning Xiaoxuan(Department of Geriatrics,The First Affiliated Hospital of Air Force Medical University,Xi'an 710032,China;Department of Endocrinology,The 940th Hospital of PLA Joint Logistic Support Force,Lanzhou 730050,China)

机构地区：[1]空军军医大学第一附属医院老年病科,西安710032 [2]中国人民解放军联勤保障部队第九四〇医院内分泌科,兰州730050

出　　处：《中华老年医学杂志》2024年第9期1210-1215,共6页Chinese Journal of Geriatrics

基　　金：国家自然科学基金面上项目(No.82270715);陕西省重点研发计划(No.2023-ZDLSF-15)。

摘　　要：钠-葡萄糖协同转运蛋白2抑制剂(SGLT2i)对2型糖尿病患者有多重获益,包括降糖降压、调节血脂、改善动脉硬化及内皮功能、减轻尿蛋白、降低尿酸等作用,在非糖尿病患者中减少肾衰竭、心血管不良事件风险方面也具有良好效果。近年来越来越多的研究发现SGLT2i具有抗衰老作用,可以延缓衰老并改善与年龄相关的疾病。本文就SGLT2i在抗衰老的方面的潜在机制进行综述,为抗衰老及预防衰老相关疾病提供参考价值。Sodium-glucose cotransporter 2 inhibitors(SGLT2i)offer numerous benefits for patients with type 2 diabetes.These benefits include lowering blood pressure and glucose levels,regulating blood lipids,improving arteriosclerosis and endothelial function,reducing urinary protein and decreasing uric acid levels.Additionally,SGLT2i has shown positive outcomes in reducing the risk of kidney failure and cardiovascular adverse events in non-diabetic patients.Recent studies have also discovered that SGLT2i has anti-aging effects,which can potentially delay aging and improve age-related diseases.This article provides a comprehensive review of the potential mechanisms of SGLT2i in anti-aging,offering valuable insights for anti-aging strategies and the prevention of aging-related diseases.

关 键 词：钠-葡萄糖协同转运蛋白2抑制剂 抗衰老 机制 

分 类 号：R977.15[医药卫生—药品]